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Abstract
Background: Alzheimer's disease (AD) is a devastating neurodegenerative disorder that affects a large
and growing number of elderly individuals. In addition to idiopathic disease, AD is also associated with
autosomal dominant inheritance, which causes a familial form of AD (FAD). Some instances of FAD have
been linked to mutations in the β-amyloid protein precursor (APP). Although there are numerous mouse
AD models available, few rat AD models, which have several advantages over mice, have been generated.
Results: Fischer 344 rats expressing human APP driven by the ubiquitin-C promoter were generated via
lentiviral vector infection of Fischer 344 zygotes. We generated two separate APP-transgenic rat lines,
APP21 and APP31. Serum levels of human amyloid-beta (Aβ)40 were 298 pg/ml for hemizygous and 486
pg/ml for homozygous APP21 animals. Serum Aβ42 levels in APP21 homozygous rats were 135 pg/ml.
Immunohistochemistry in brain showed that the human APP transgene was expressed in neurons, but not
in glial cells. These findings were consistent with independent examination of enhanced green fluorescent
protein (eGFP) in the brains of eGFP-transgenic rats. APP21 and APP31 rats expressed 7.5- and 3-times
more APP mRNA, respectively, than did wild-type rats. Northern blots showed that the human APP
transgene, driven by the ubiquitin-C promoter, is expressed significantly more in brain, kidney and lung
compared to heart and liver. A similar expression pattern was also seen for the endogenous rat APP. The
unexpected similarity in the tissue-specific expression patterns of endogenous rat APP and transgenic
human APP mRNAs suggests regulatory elements within the cDNA sequence of APP.
Conclusion: This manuscript describes the generation of APP-transgenic inbred Fischer 344 rats. These
are the first human AD model rat lines generated by lentiviral infection. The APP21 rat line expresses high
levels of human APP and could be a useful model for AD. Tissue-specific expression in the two transgenic
rat lines and in wild-type rats contradicts our current understanding of APP gene regulation.
Determination of the elements that are responsible for tissue-specific expression of APP may enable new
treatment options for AD.
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Background
Alzheimer's disease (AD) is a devastating neurodegenera-
tive disorder that affects 7–10% of elderly individuals over
65 years of age and nearly 50% of those over 85 in the U.S
[1]. AD also can be inherited in an autosomal dominant
manner, which causes a familial form of AD (FAD) that
usually emerges at younger ages than does idiopathic AD
[2]. FAD has been linked to mutations in the β-amyloid
precursor protein (APP) [3], as well as presenilin 1 [4] and
presenilin 2 [5], which are critical components of the γ-
secretase complex that liberates the amyloid-β peptide
(Aβ) from membranes. Aβ is the major proteinaceous
component of senile plaques, and all known FAD muta-
tions increase the production of Aβ or its tendency to
aggregate. Two predominant forms of Aβ, Aβ40 and Aβ42,
result from the proteolytic cleavage of APP by β- and γ-
secretases [6]. Because it is highly amyloidogenic, Aβ42 is
believed to play a particularly important role in the patho-
genesis of AD [7].
Several transgenic (Tg) mouse models of AD have been
generated to study the effects of APP mutations. The
genetic background of mice has been shown to have a sig-
nificant effect on plasma and brain Aβ40 and Aβ42 levels as
well as on Aβ-deposition in brain [8]. Outbred mouse
lines show variability in Aβ production and deposition,
whereas Aβ production is more consistent within an
inbred transgenic line. In this regard, the generation of
transgenic rats on various genetic backgrounds (i.e. inbred
Lewis and Fischer 344 strains) has been more difficult
than mice and outbred rats (i.e. Sprague Dawley and Wis-
tar) [9]. Recently, outbred single-transgenic rats have been
generated that express either human wild type [10] or
mutant APP [11,12]. Transgenic Wistar rats overexpress-
ing human APP695 (hAPP695) were used to investigate
the role of APP in the recovery process following cerebral
ischemia [10]. The authors report that despite the total
APP/Aβ levels in cortex and hippocampus of hAPP695
rats being twice the level of non-transgenic controls,
hAPP695 did not develop amyloid plaques with aging. Tg
Wistar rats overexpressing the APPSw/Ind transgene showed
some intraneuronal Aβ immunoreactivity but failed to
develop β-amyloid deposits by 24 months of age [11].
Recently, Folkesson et al. [12] reported the development
of an outbred SD rat line expressing APPSw which begin to
show extracellular Aβ that is predominantly found in cer-
ebrovascular blood vessels beginning at 15 months of age.
Ruiz-Opazo et al. [13] reported generation of inbred
APPSw Fischer-344 rats with a 56.8% increase in APP
mRNA expression in the brain of transgenic animals com-
pared to non-transgenic cohorts at 12-months of age. The
APPSw Fischer-344 rats did not show evidence of extracel-
lular amyloid deposits or senile plaques up to 18 months
of age. Interestingly, APPSw Fischer-344 rats showed atten-
uated hippocampus-dependent learning and memory
decline compared to non-transgenic cohorts as measured
by Morris Water Maze. Ruiz-Opazo [13]and colleagues
have postulated that within a particular expression range
APP or its derivatives my play a role in normal learning
and memory, but when expressed at levels exceeding this
threshold APP and/or its metabolites could lead to neuro-
nal loss and cognitive decline.
Although mice have been extensively used in many areas
of biomedical research, rat models have certain advan-
tages over mice due to their larger size, unique genetics,
and well-studied behavioral characteristics [14]. Rats are
better suited for microsurgery, cell and tissue transplanta-
tion, in vivo functional analyses, and studies that require
multiple sampling [15]. In the context of neurological
studies, stereotaxic injection is a commonly used method
that is easier to perform with precision in rats than in
mice. For these reasons, it is advantageous to have germ-
line Tg rat models of neurodegenerative diseases like AD
in order to better understand the underlying biochemical
changes taking place during disease development and to
test potential treatment options. The AD rat models devel-
oped previously were generated mostly on outbred rat
strains. Our aim was to develop an inbred APP transgenic
rat line with high APP expression in the brain, as we
believe this may be one of the important prerequisites for
producing amyloid pathology in rat models of AD.
Results
Promoter Characterization and Selection
Comparison of enhanced green fluorescent protein
(eGFP) expression driven from ubiquitin-C (Ubi-C),
cytomegalovirus (CMV), or platelet-derived growth factor
(PDGF) promoters in SD rat brains after stereotaxic injec-
tion of lentivirus showed that the Ubi-C promoter yielded
consistently superior eGFP expression than did the CMV-
eGFP and PDGF-eGFP viruses. Figure 1 shows eGFP
expression in rat brains three weeks post-injection of Ubi-
C-eGFP and CMV-eGFP lentiviruses. Enhanced GFP
expression driven by CMV and PDGF promoters appeared
to decrease dramatically over time. In contrast, strong
Ubi-C- eGFP expression persisted without apparent dimi-
nution at the longest time-point examined (13 months,
data not shown). These results with Ubi-C are consistent
with previous findings using the Ubi-C promoter in driv-
ing transgene expression [16].
While stable, high-level transgene expression is highly
desirable in Tg animals, neuron-selective expression is
also an important consideration in selecting an optimal
promoter. Brain expression of the eGFP transgene driven
by a Ubi-C promoter was examined in Tg SD rats created
by injection of eGFP-lentivirus into fertilized zygotes.
Strong eGFP expression was seen in adult rats; by confocal
microscopy, eGFP expression appeared to be restricted toBMC Neuroscience 2008, 9:28 http://www.biomedcentral.com/1471-2202/9/28
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neurons (Fig. 2). When eGFP distribution was directly
compared to immunostaining with glial fibrillary acidic
protein (GFAP) to label astrocytes, there was strong diver-
gence in the staining patterns. To confirm the apparent
restriction of eGFP driven by the Ubi-C promoter to neu-
rons, primary cultures were established from E18 Tg SD
embryos and employed for colocalization studies using
markers for neurons and glial cells. Confocal images of
mixed primary cultures stained with neuron-specific beta
tubulin and GFAP is shown in Figure 2J. Enhanced GFP is
expressed in neurons, but not in glial cells, confirming the
neuronal specificity of eGFP expression driven by the Ubi-
C promoter.
Transgenic Founders
Table 1 summarizes the Tg rates following lentiviral deliv-
ery of the APPSw/Ind double mutant construct. We injected
a total of 168 zygotes, transferred 156 of them to recipient
foster mothers, and obtained 18 live pups as a result. Both
PCR and Southern analysis revealed 4 Tg founder pups
carrying the APPSw/Ind double mutant transgene. The Tg
rate based on the numbers of Tg pups born/numbers of
embryos transferred was 22% (4/18). Aβ ELISA assess-
ment revealed that two (APP21 and APP23) of these 4
founders had detectable levels of human Aβ40 in serum
samples by 9 weeks of age (140 and 126 pg/ml, respec-
tively).
Initial Screening of APP-Transgenic Founders and 
Generation of Homozygous Transgenic Rats
Four PCR- and Southern blot-positive APPSw/Ind Tg rats
were generated (Fig. 3). Two of the founders were germ-
line Tg (APP21 and APP31) and each had a single copy of
the transgene. The other two were not germline Tg (APP23
and APP30) and each contained two copies of the trans-
gene. The molecular weights of DNA fragments contain-
ing the transgene that were obtained through BamHI
digestion were 10 and 6 kb for APP21 and APP31 lines,
respectively. EcoRI digestion of genomic DNA yielded 6.5
and 5 kb fragments for APP21 and APP31 lines, respec-
tively. Both APP21 and APP31 Tg lines contained one
copy of the transgene as determined by two separate
restriction enzyme digestions (EcoRI and BamHI; Fig. 3).
Different molecular weights of the transgenes in APP21
and APP31 animals is due to different transgene integra-
tion sites in these two transgenic lines. Both APP21 and
APP31 lines were bred for five generations, demonstrating
the stability of the transgene across generations; both lines
appear normal and do not have any indication of unpre-
dicted side effects of the transgenes.
APP Transgene Expression
Expression of the APP transgene was determined by
Northern blot analysis in homozygous rats (Fig. 4). The
APP probe used for Northern blot analysis hybridizes
both the human APP transgene as well as native rat APP.
The BLAST score (NCBI, Bethesda, MD) of the 773 bp
human APP probe template to rat APP mRNA was 547.
The molecular weight of the APP mRNA was approxi-
mately 2.5 kb. Northern blot analysis showed that the
APP21 line expressed the highest levels of APP mRNA, the
APP31 line expressed intermediate levels (Fig. 4 and 5A),
and the native rat APP mRNA expression was the lowest.
Expression of APP showed a tissue-dependent variation.
The transgene was highly expressed in kidney and lung of
both the APP21 and APP31 lines. Expression in brain was
intermediate, and expression in liver and heart was the
lowest for both Tg lines (Fig. 4 and 5A). Similar expression
patterns for rat APP mRNA were observed in non-trans-
genic rats, such that liver and heart contained lower APP
compared to brain, kidney and lung. The average expres-
sion among the organs analyzed was 4.3 times lower in
WT rats than in APP Tg rats. Brain APP expression in the
APP21 line was 1.7 and 2.9 times greater than in APP31
and WT rats, respectively (Fig. 5B).
Aβ ELISA
Serum levels of human Aβ40  were determined in
homozygous APP21 (n = 2), APP31 (n = 3), and
hemizygous APP21 (n = 16) rats. In addition, 26 rats from
two Tg parents, denoted as 'homozygosity status
unknown', were included in the statistical analysis (Table
2). Serum Aβ40 was measurable in all APP21 animals, and
Comparison of promoters following lentivirus injection in rat  brain Figure 1
Comparison of promoters following lentivirus injection in rat 
brain. Lentiviruses were stereotaxically injected into rat hip-
pocampus and examined after three months. A. eGFP 
expression driven by the ubiquitin-C promoter (Ubi-C) was 
consistently superior to that of other promoters, including 
the platelet-derived growth factor promoter (PDGF) and 
cytomegalovirus. Lower panels show representative higher 
power images of eGFP driven by Ubi-C- (B), cytomegalovi-
rus- (C), and PDGF- (D) promoters in lentivirus/eGFP-
injected rats.BMC Neuroscience 2008, 9:28 http://www.biomedcentral.com/1471-2202/9/28
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homozygous rats had 1.6 times greater Aβ40 than did
hemizygous rats. Average serum Aβ40 levels of the APP31
line were 5 times lower than those of the APP21 line. In
addition, Aβ40 was undetectable in 10 out of 20 rats,
which includes 3 homozygous rats. Serum levels of Aβ42,
measured in two APP21 homozygous rats, were 135 ± 64
pg/ml. Only one out of eleven APP31 rats had measurable
levels of Aβ42.
Brain Immunohistochemistry
Figure 6 shows a representative section from a two month-
old homozygous male derived from founder #21. The low
power micrograph (Fig. 6A) demonstrates widespread
expression of human APP in the cortex and hippocampus
detected by human APP-specific staining with antibody
6E10. The distribution of staining shows strong neuronal
expression in neocortex, hippocampal dentate granule
cells, and hippocampal pyramidal neurons. No staining
was observed in control sections when primary antibody
eGFP expression in the brain of a transgenic rat (Ubi-C promoter) Figure 2
eGFP expression in the brain of a transgenic rat (Ubi-C promoter). Upper panel: eGFP expression is restricted to neurons in 
transgenic rat brain. A. Confocal microscopy shows extensive eGFP expression in dentate granule cells. B. GFAP immunoreac-
tivity reveals astroglial cells. C. Merged images show a lack of colocalization of eGFP and GFAP signals. Middle panel: confocal 
images reveal robust eGFP expression in neuronal cell bodies. D. Cortex. E. Striatum. F. CA1 region of hippocampus. G. Hip-
pocampal dentate gyrus. Lower panel: Mixed primary cultures from E18 embryos were stained with anti-beta III tubulin to 
identify neurons (I; red) and GFAP to label glial cells (J; purple). eGFP expression in cultured neurons was concentrated in the 
nucleus as well as the cytoplasm (H; green). Arrowheads denote individual neurons in all panels, and the merged image (K) 
shows eGFP in neurons but not in glial cells.
Table 1: Transgenic efficiency after injection of lentiviral vectors carrying the APPSw/Ind double mutation under control of the ubiquitin-
C promoter in Fischer 344 rat zygotes.
Zygotes injected Embryos transferred Live pups born Transgenic pups Germline transgenic
168 156 (93%) 18 (12%) 4 (22%) 2 (50%)BMC Neuroscience 2008, 9:28 http://www.biomedcentral.com/1471-2202/9/28
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was omitted [see Additional file 1]. Higher power images
show punctate cytoplasmic staining in large cortical
pyramidal neurons (Fig. 6B) and hippocampal pyramidal
cells (Fig. 6C). Unexpected selectivity was noted in the
hippocampus, where intense staining was seen in CA3
and CA1 neurons, but 6E10 staining appeared to demar-
cate the margins of CA2, which was largely devoid of
staining. High power images demonstrate the absence of
human APP transgene expression in glial cells. Staining
with an antibody directed against the glial fibrillary acidic
protein (GFAP), a marker for astrocytes and the glia, dem-
onstrates the absence of human APP transgene expression
in glial cells (Fig. 6D) of the cortex (Fig. 6E) or hippocam-
pus (Fig. 6F).
APP Transgene Expression in C3-3 Mice
Human APP cDNA expression in Tg C3-3 mice [17] was
analyzed to determine if a different promoter, the prion
protein promoter (PrP), would also drive the expression
of the human APP cDNA in a tissue-specific manner sim-
ilar to that observed in APP21 and APP31 Tg rats. North-
ern blotting results (Fig. 7) showed that transgenic APP
expressed tissue-specifically in C3-3 mice as well. The
transgenic APP expression was highest in brain, heart, kid-
ney and lung, but very little APP expression was detected
in the liver of C3-3 mice. Relative expression in brain, kid-
ney, liver and lung was similar in APP21 and APP31 rats
and C3-3 mice. However, in C3-3 mice, expression of APP
in heart was similar to APP expression levels in brain, kid-
ney and lung. Intriguingly, these two different Tg species
(mouse and rat), in which the APP cDNA transgene is
under the control of two unrelated promoters, show a
similar pattern of tissue-specific expression
Discussion
This study demonstrates the efficacy of generating inbred
Tg rats using a lentiviral vector, which is a novel approach
for generating Tg animals [18]. Despite dozens of Tg
mouse models of AD-like pathology, few Tg rat lines are
available for AD research [10-13]. Since the manifestation
of specific genetic disorders in transgenic models is
expected to be unique to each species and strain, it is
essential to control phenotypic variations that stem from
the genetic constitution of the background strain. Thus we
chose the inbred Fischer 344 rat strain for transgenic pro-
duction in order to minimize individual variation among
transgenic rats. In transgenic mouse models of AD, Leh-
man et al. [8] reported that genetic background had a sig-
nificant influence on the regulation of APP and Aβ
deposition in Tg mice that were created on different
genetic backgrounds. For our studies, we chose inbred
Fischer 344 rats due to their well-defined genetics as well
as their common usage in studies involving aging [19]. As
Fischer 344 rats age, their brains are increasingly suscepti-
ble to oxidative stress, which is known to correlate with
many neurodegenerative diseases, including AD. How-
ever, the approach that we employed to create germline Tg
APPSw/Ind  lines using Fischer 344 rats can be equally
applied to other strains, providing unrestricted opportu-
nities to create disease models on various genetic back-
grounds.
Southern blot hybridization of genomic DNA obtained from  APP21 and APP31 rats Figure 3
Southern blot hybridization of genomic DNA obtained from 
APP21 and APP31 rats. A. Genomic DNA from APP21 (116, 
117, 118, 121, 124, 125) and APP31 (31, 86, 88) animals were 
digested with BamHI and hybridized with a human APP 
probe. B. Genomic DNA from APP31 (31, 86, 88) and 
APP21 (116, 117, 118, 121, 124, 125) were digested with 
EcoRI and hybridized with a human APP probe.BMC Neuroscience 2008, 9:28 http://www.biomedcentral.com/1471-2202/9/28
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In this paper, we report the successful generation of
APPSw/Ind Tg Fischer 344 rats expressing human APP695
containing the Swedish and Indiana mutations under the
control of the Ubi-C promoter using a lentiviral vector.
The APP695 form was chosen because the predominant
human APP isoform expressed in neurons of the central
nervous system (CNS) is the APP695 isoform [20]. Addi-
tionally, we chose to construct the double-mutant
APP695 transgene to facilitate comparisons with existing
Northern blot hybridization of total RNA from tissues of the APP31 and APP21 lines as well as WT rats Figure 4
Northern blot hybridization of total RNA from tissues of the APP31 and APP21 lines as well as WT rats. Total RNA hybridized 
with the human APP probe (upper autoradiogram) prior to hybridization with 18S rRNA (lower autoradiogram). B: Brain, H: 
Heart, K: Kidney, Li: Liver, Lu: Lung.
Gene expression differences among organs obtained from APP21, APP31 and WT rats Figure 5
Gene expression differences among organs obtained from APP21, APP31 and WT rats. A. The expression of APP genes is nor-
malized by dividing the net intensity of APP bands by the 18S rRNA bands. ** represent significantly greater APP expression in 
APP21 compared to APP31 and WT rats (P < 0.05); * represents significantly greater APP expression in APP31 compared to 
WT rats (P < 0.05). B. APP expression-difference between APP21 and APP31 rats compared to WT animals. The values were 
obtained by dividing the APP expression in each organ (B: Brain, H: Heart, K: Kidney, Li: Liver, Lu: Lung) by APP expression in 
WT rats.BMC Neuroscience 2008, 9:28 http://www.biomedcentral.com/1471-2202/9/28
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APP695 transgenic mouse and rat models, particularly the
Tg2576 mice reported by Hsiao et al. [21].
Long-lasting neuronal expression of transgenes is an
important consideration in modeling neurodegenerative
diseases such as AD. Our earlier efforts to create Tg APP-
and PS1-overexpressing SD rats under the control of the
CMV promoter using lentiviral vectors were successful in
terms of efficient gene delivery. However, the Tg rats did
not have the desired level of gene product as assessed by
ELISA and Western blot analysis, even at 10 months of age
(unpublished data). This lack of expression may be attrib-
utable to the phenomenon of gene silencing, which has
previously been observed with a number of promoters,
including CMV. In the present study, the easily detectable
eGFP reporter gene was used to compare eGFP expression
after stereotaxic injection of lentiviral vectors containing
various promoters. In these studies, CMV, PDGF, and Ubi-
C promoters all drove high-level expression of eGFP in-
vitro. However, when tested in vivo after stereotaxic injec-
tion or creation of Tg animals, CMV-eGFP and PDGF-
eGFP expression decreased dramatically over time,
whereas eGFP expression remained strong for up to 13
months when driven by the Ubi-C promoter. Characteri-
zation of transgene expression in rat brains revealed long-
lasting and selective neuronal expression of genes driven
by the Ubi-C promoter. Stereotaxic injections were used to
Table 2: Serum Aβ40 levels of homozygous and hemizygous 
APP21 and APP31 lines determined by ELISA. h?: homozygosity 
status not determined; he:hemizygous; ho: homozygous; SE: 
Standard error; N: number of rats included in the statistical test; 
P: P value. All rats in the APP21 line had measurable levels of 
Aβ40 in serum. The Aβ40 levels were out of range in 10 of 20 rats 
in the APP31 line.
Aβ40 (pg/ml) SE N Age, d P
APP21 h? 466.2A 46.2 9 61 <.0001
APP21 he 298.2A 34.7 16 151 ± 81 <.0001
APP21 ho 486.0A 98.0 2 70 <.0001
APP31 h? 93.2B 33.6 17 81 ± 42 0.0083
APP31 ho 0.0B 80.0 3 107 1
Human APPSw/Ind expression in transgenic rat brain Figure 6
Human APPSw/Ind expression in transgenic rat brain. A. A low power (2×) micrograph demonstrates widespread expression of 
human APP in the neocortex and hippocampus. Higher power (20×) images show punctate cytoplasmic staining in large corti-
cal pyramidal neurons (B) and hippocampal pyramidal neurons (C). APP staining appears to demarcate the margins of CA2 
pyramidal neurons, which were largely devoid of staining (C). Low power (2×) micrograph of an adjacent section stained with 
an anti-GFAP antibody. GFAP staining reveals the presence of glia and astrocytes within the neocortex and hippocampus (D). 
Higher power (20×) images from the cortex (E) and hippocampal dentate gyrus (F) are shown for comparison to (B-C) and 
illustrate that human APPSw/Ind expression in occurring predominately in neurons.BMC Neuroscience 2008, 9:28 http://www.biomedcentral.com/1471-2202/9/28
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qualitatively screen CMV, UbiC, and PDGF promoters for
ability to drive eGFP transgene expression within the hip-
pocampus. The choice of SD rats was based on the use of
this strain in the stereotaxic mapping of the rat brain by
Paxinos & Watson [22]. The dentate gyrus injection coor-
dinates extrapolated from the atlas have been experimen-
tally verified in our laboratory using SD rats and therefore
we used SD rats to examine eGFP expression from the
CMV, UbiC, and PDGF promoters. The goal of the pro-
moter comparisons was not to characterize the expression
patterns of the CMV, UbiC, and PDGF promoter in the
CNS, which has previously been well documented, but
rather to show qualitative examples of eGFP expression
within the hippocampus following focal injection of len-
tivirus. Stereotaxic injections were performed in dentate
gyrus to allow qualitative assessment of gene expression
within the hippocampal formation, a region particularly
vulnerable to neuropathological insult in AD. We deter-
mined that the eGFP signal consistently appears to be
both nuclear and cytoplasmic in vitro and in vivo, regard-
less of the method of transgene delivery or type of pro-
moter. Similar results were obtained by Wei et al. [23],
who showed that eGFP diffused bidirectionally via the
nuclear pore complex across the nuclear envelope.
To our knowledge, this is the first inbred, APP-transgenic
rat model of AD that has substantial quantities of Aβ in
serum. Prior to the generation of APP21 and APP31 trans-
genic rat strains, a Fischer 344 inbred AD model express-
ing APP (TgAPPSw) was reported by Ruiz-Opazo et al.
[13]. However, APP expression in these TgAPPSw rats was
only 56% greater than in WT rats. In addition, APP-trans-
genic, outbred Wistar rats expressed 2.5 times more APP
in hippocampus than did control rats [24] In the current
paper, we report 2.9 times greater APP expression in the
brains of inbred Fischer 344 rats than in WT controls. Due
to the higher APP expression, APP21 rats could be useful
models for examining the underlying mechanisms of AD
progression and for developing and testing potential ther-
apies for AD.
Several mouse models have been generated to study the
effects of APP mutations. Hsia et al. [25] generated Tg
APPSw/Ind mice. The characterization of these Tg mice indi-
cated that the neurotoxic effects of Aβ may not require
plaque formation. APP23 mice express 7-fold more APPSw
than endogenous mouse APP and develop Aβ deposits at
6 months of age [26]. Tg APP mice were generated using
tissue-specific promoters such as enolase, platelet derived
growth factor, and Thy-1 [27-29]. Similarly, we show that
promoter choice significantly influences the expression of
the transgene, such that Ubi-C is superior to CMV and
PDGF in rats. The present study describes the generation
of APP Tg Fischer 344 rats under the control of the Ubi-C
promoter, which drives transcription in all tissues rela-
tively stably. The expression of APPSw/Ind transgenic mRNA
was detectable in all tissues analyzed for both the APP21
and APP31 lines. The expression of transgene was greater
in the APP21 line than in the APP31 line. Since these Tg
rats were generated as models of AD-like pathology, the
expression level of the transgene is particularly important.
The APP21 line showed 3 times greater cerebral APP
expression compared to WT rats. The expression of brain
APP in the APP31 line was about half that of the APP21
line. In addition, serum Aβ40 levels corroborate these find-
ings. The APP21 line had significantly greater human Aβ40
than did the APP31 line. In transgenic mouse models, the
expression of APP has reached levels as high as 10-fold
greater than endogenous APP [28]. However, protein
expression level is not the only determinant of AD pheno-
type, as lower expression of mutant forms of APP can
Gene expression analysis of APP-transgenic mice Figure 7
Gene expression analysis of APP-transgenic mice. A. North-
ern blot hybridization of total RNA from C3-3 APP-trans-
genic mouse tissues. Total RNA hybridized with a human 
APP probe (upper autoradiogram) prior to hybridization 
with 18S rRNA (lower autoradiogram). B. Gene expression 
differences among organs obtained from C3-3 mice. The 
expression of APP genes was normalized by dividing the net 
intensity of APP bands by the 18S rRNA bands. Different let-
ters above the bars represent statistically significant (P < 
0.05) expression levels. B: Brain, H: Heart, K: Kidney, Li: 
Liver, Lu: Lung.BMC Neuroscience 2008, 9:28 http://www.biomedcentral.com/1471-2202/9/28
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induce early and robust deposition of Aβ in brain paren-
chyma and/or vasculature [29,30].
While the anticipation of stable transgene expression was
a key consideration in selecting the Ubi-C promoter for
our studies, selective neuronal expression driven by this
promoter was unexpected. Our observations in brain and
primary cultures from eGFP-transgenic SD rats confirmed
the highly preferential expression of eGFP in neurons ver-
sus glial cells (Fig. 2). Potentially even greater levels of
selectivity are suggested by our characterization of APPSw/
Ind expression in transgenic Fischer 344 rats. In these ani-
mals, human APP was strongly expressed in neurons, but
within the hippocampus, there was a strong demarcation
based on the intensity of immunostaining in the pyrami-
dal cell layer between CA1 and CA2 (Fig. 6). The basis for
this selectivity is unclear, and additional studies will be
required to fully evaluate the distribution of Ubi-C pro-
moter-driven transgene expression in brain.
We chose Northern blot analysis to assess gene expression
in APP21 and APP31 transgenic and WT rats and C3-3
mice. This allowed us to confirm the size of the complete
transcript in the transgenic animals. Samples collected
from brain yield a higher band for APP mRNA and 18S
rRNA for both rat and mouse samples. Since both APP
mRNA and 18S rRNA migration was retarded in brain
RNA samples compared to the rest of the organs, we sus-
pect that brain RNA samples contain residual substances
that impede the migration of brain RNA. These could be
residual lipids, as the brain contains more fat compared to
the other organs analyzed.
Since the sequences of human and rat APP are highly sim-
ilar, the APP probe used for Northern blot analysis did not
distinguish between human and rat APP. This enabled
comparison of native rat APP- and human APP-transgene
expression. The transgene as well as the endogenous rat
APP gene expression patterns showed significant tissue-
specificity. Interestingly, both the human APP transgene
and endogenous rat APP mRNA were more abundant in
kidney and lung than in heart and liver. Although tissue-
specific expression of APP in humans was reported previ-
ously [31], tissue-specific expression of the APP transgene
was unexpected in the transgenic rats because the Ubi-C
promoter drives expression of the human APP transgene
in this construct. We have generated purinergic receptor
Y2- (P2RY2) transgenic rats using the same vector back-
bone, and expression of the P2RY2 transgene driven by
the Ubi-C promoter did not show tissue-specificity
(unpublished data).
Tissue specific expression of APP transgene can be due to
APP mRNA stability, RNA silencing or transcription regu-
latory elements within APP cDNA. The 3'UTRs of human,
rat and transgenic APP are substantially different which
reduces the possibility of tissue specific differences in APP
mRNA stability. In addition, we were unable to find a can-
didate sequence for RNA silencing within the rat or
human genome. Thus, regulation through enhancer or
silencer elements within the APP cDNA is a possible
explanation for tissue-specific expression regardless of the
promoter that drives the expression of APP. A recent pub-
lication by Collin and Martens [32] supports the presence
of transcription regulatory role of APP cDNA.
In order to confirm tissue-specific expression of APP, we
analyzed APP transgene expression in C3-3 transgenic
mice, which is driven by the ubiquitously expressed prion
protein promoter [17]. Expression levels of endogenous
prion protein are similar in various tissues. We suggest
that the similarity of tissue-specific expression patterns of
APP transgenes that are driven by two different promoters
(Ubi-C and PrP) in two different species (rat vs. mouse)
strongly supports the presence of transcription regulatory
elements within the APP cDNA. The temporal and spatial
expression differences in APP-transgenic mice have been
attributed to the promoters (PDGF, and Thy-1) used to
drive expression [33]. However, we believe that the
changes in APP expression patterns shown in our study
cannot be explained by the promoter because of the stable
expression driven by the Ubi-C promoter in most tissues.
We hypothesize that elements within the cDNA sequence
may regulate the expression of APP tissue-specifically.
Identification of these elements might ultimately broaden
treatment options for AD. In conclusion, these APP-trans-
genic rats could be a useful model in which to study the
regulation of APP expression as well as pathogenic mech-
anisms in AD.
Conclusion
This study shows the high efficiency of establishing stable,
inbred germline transgenic rats by lentiviral gene delivery.
The APP21 rats, which express high levels of human APP,
could be a valuable model of AD. Furthermore, the tissue-
specific expression of the APP transgene indicates the
presence of regulatory elements within APP cDNA that
could be a useful target for AD treatment or prevention.
Our ongoing studies are aimed at intensive pathological
and behavioral characterization of these unique APP-
transgenic rats.
Methods
Construct Design and Preparation of VSV-G Pseudotyped 
Lentivirus
Human APP (695 amino acid isoform) was mutagenized
using the QuickChange II XL site-directed mutagenesis kit
(Stratagene, La Jolla, CA) to incorporate the Swedish dou-
ble missense mutation (K595M/N596L) and Indiana sin-
gle missense mutation (V642F). The APP sequence wasBMC Neuroscience 2008, 9:28 http://www.biomedcentral.com/1471-2202/9/28
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cloned into the pLVU-eGFP cassette [18] in place of the
eGFP coding sequence. The new vector was designated as
pLVU-APPSw/Ind. The APP transcription was under the con-
trol of the Ubi-C promoter. In brief, pLVU-APPSw/Ind is a
self-inactivating vector, composed of the woodchuck hep-
atitis virus post-transcriptional regulatory element (WRE)
to increase transcription level and minimize position
effect. Additionally, an HIV-1-flap element was inserted
between the 5'LTR and the internal promoter, which
increases titer (Fig. 8). Preparation of VSV-G Pseudotyped
Lentivirus was as described [18].
Promoter Characterization
To select an advantageous promoter to drive transgene
expression in brain, lentiviruses were constructed using
Ubi-C, CMV, and PDGF promoters to drive expression of
eGFP. Lentiviruses were stereotaxically injected into the
hippocampus of SD rats. Qualitative comparisons of
eGFP expression were made 3 weeks and 3 months fol-
lowing injection. To characterize Ubi-C promoter driven
transgene expression, eGFP-transgenic SD rats were cre-
ated as described below and analyzed by confocal micro-
scopy.
Cell Culture
Rat primary E18 cortical cultures were established from
timed-pregnant female SD females that were bred to eGFP
Tg males. Mixed neuronal and glial cultures were plated
on polylysine-coated coverslips and processed for
immunofluorescence. Neurons were identified by immu-
nostaining with anti-beta III tubulin (Promega, Madison,
WI), and astrocytes were labeled with anti-GFAP (Dako,
Carpinteria, CA).
Stereotaxic Injection
Lentiviruses were injected stereotaxically into the hippoc-
ampus of adult male SD rats weighing 250–300 g. Rats
were anesthetized by IM injection of ketamine-xylazine
and positioned in a Kopf Small Animal Stereotaxic Instru-
ment (David Kopf Instruments, Tujunga, California). One
microliter of lentivirus was injected bilaterally into the
dentate gyrus at the following coordinates with respect to
bregma: AP -3.30 mm, ML +/- 1.6 mm, DV 3.2 mm. A 5-
μl Hamilton syringe was used to deliver virus at a rate of
150 nl/min.
Zygote Collection, Microinjection of Lentiviral Vector and 
Embryo Transfer
Fischer 344 female rats (28–30 day-old) were purchased
from Harlan Sprague Dawley Inc. (Indianapolis, IN) and
superovulated using follicle-stimulating hormone and
luteinizing hormone; zygotes were collected after mating
[34]. Morphologically normal zygotes having two pronu-
clei were used for lentiviral vector injections as described
earlier [18]. Lentiviral vector-injected zygotes were then
transferred into the oviducts of 8–10 week-old pseudo-
pregnant recipient rats.
Breeding of Transgenic Rats
Fischer 344 Tg founders were mated with WT Fischer 344
rats to determine germline transgenesis. After germline
transgenesis was confirmed, rats from the F1 generation
were used to generate homozygous Tg rats. Homozygosity
was initially determined by Southern blot hybridization.
Conventional matings were used to confirm the homozy-
gosity of Tg rats. All animal studies were performed in
accordance with the University of Missouri's Animal Care
and Use Committee guidelines and the ILAR Guide for the
Care and Use of Laboratory Animals. The rats were housed
in conventional cages at 20–25°C in a controlled lighting
environment and provided free access to water and stand-
ard pelleted rodent chow. Rats were euthanized with an
inhaled overdose of CO2.
Genomic DNA Isolation and Polymerase Chain Reaction
Genomic DNA from tail-snips was isolated using the Wiz-
ard Genomic DNA Purification Kit (Promega, Madison,
WI). PCR was used for screening of Tg rats. Primers
annealing the Ubi-C promoter (TGTCCGCTAAATTCT-
GGCCGTT) and APP transgene (ATTTCGAGCATGTGCG-
CATGGT) were used in the PCR reactions. The 50 μl
reactions were carried out using 50 ng genomic DNA, 100
ng of each primer and 1.5 U Biolase taq (Bioline, Ran-
dolph, MA). The amplified PCR products were size-sepa-
rated through 1% agarose gel and stained with ethidium
bromide for visualization.
Southern blot Analysis
Southern blot analysis was done to determine the copy
number as well as homozygosity of the Tg rats. Genomic
DNA was digested with BamHI or EcoRI, which only cut
the junction of the human Ubi-C promoter and APP
DNA construct of pLVU-APPSw/Ind Figure 8
DNA construct of pLVU-APPSw/Ind. LTR: long terminal repeat; UB: ubiquitin-C promoter; APP: human amyloid precursor pro-
tein; WRE: woodchuck hepatitis virus post-transcriptional regulatory element.BMC Neuroscience 2008, 9:28 http://www.biomedcentral.com/1471-2202/9/28
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transgenes or the junction of APP and WRE transgenes,
respectively. The digestion products were size-separated
through a 0.8% agarose gel and transferred to a Gene-
screen plus membrane (Perkin Elmer, Wellesley, MA)
overnight. The 773 bp APP probe template was prepared
by amplification of pLVU-APP using forward (TGTT-
GCCCACTGGCTGAAGAAA) and reverse (ATTTCGAG-
CATGTGCGCATGGT) primers. The 32P labeled probe was
generated using the probe template, Ready-To-Go DNA
Labeling Beads (Amersham Biosciences, Piscataway, NJ)
and [α-32P]-dCTP (Perkin Elmer, Wellesley, MA). The
membranes were prehybridized in 10% dextran sulfate,
6× SSC, 1% SDS for 2 hours and hybridized using the 32P
labeled probe overnight before exposing to BioMax MS-1
Autoradiography Film (Kodak, Rochester, NY). To deter-
mine homozygosity, the membranes were hybridized
with P2RY2 probe following hybridization with the APP
probe. P2RY2 was used as a positive control for homozy-
gosity to correct for pipetting differences between the sam-
ples. The intensity of bands was determined using Kodak
1D v 3.6.3 software (New Haven, CT).
Northern blot Analysis
Total RNA was isolated using Trisure (Bioline, CA) from
APP21 (n = 2), APP31 (n = 3), and WT (n = 3) rats as well
as APP-transgenic C3-3 mice (n = 3). Brain, heart, kidney,
liver and lung tissues were used in Northern blot analysis.
Total RNA was size-separated through 1% agarose gel
before transferring to the Genescreen plus membrane
overnight. The membrane was prehybridized in 10% dex-
tran sulfate, 5× SSPE, 50% formamide, 5× Denhardt's, 1%
SDS at 42°C for 6 hours prior to hybridization with the
APP probe overnight. Membranes were subsequently
hybridized with an 18S rRNA probe to correct for pipet-
ting differences. Intensity of bands was determined using
Kodak 1D v 3.6.3 software (New Haven, CT).
ELISA Measurement of Aβ40 and Aβ42
To screen for transgene expression, serum samples were
collected and assayed for Aβ40 and Aβ42 using commercial
ELISA kits (Genetics Company, Schlieren, Switzerland).
Serum samples were diluted in assay buffer and processed
according to the manufacturer's recommended protocols.
Briefly, samples and standards were incubated in capture
wells overnight at 4°C with biotinylated Aβ40 or Aβ42-spe-
cific antibody. After several rinses, the enzyme-conjugated
detection reagent was added to the wells for 30 minutes.
After additional rinses, wells were incubated with the
chromogen solution for 30 minutes at room temperature,
shielded from light. After addition of the stop solution,
the wells were read for absorption at 450 nm, and Aβ con-
centration in the samples was calculated from standard
curves.
Brain Immunohistochemistry and Confocal Microscopy
Hemi-brains of human APP Tg rats were immersion-fixed
with 4% paraformaldehyde for 3 hours at 4°C, then cryo-
protected in 30% sucrose prior to sectioning on a freezing-
sliding microtome to obtain 50 μm-thick sagittal sections.
Immunohistochemical processing was performed using
free-floating sections and immunoperoxidase methods.
Sections were treated with hydrogen peroxide, washed in
Tris buffer, blocked with normal serum, and incubated
with human-specific 6E10 mouse monoclonal anti-APP
antibody (Signet; Dedham, MA) or rabbit polyclonal anti-
GFAP (DAKO; Carpinteria, CA). On day 2, sections were
incubated with biotinylated secondary antibody followed
by the avidin-biotin-peroxidase complex for 1 hour at
4°C (Vector Elite ABC kit; Vector Laboratories, Burlin-
game, CA). Immunoreactivity was visualized with 3, 3'-
diaminobenzidine tetrahydrochloride. For high-resolu-
tion light microscopic localization, confocal images were
captured on a Zeiss LSM510-NLO microscope using 1 μm
optical sections. For promoter comparisons, sections were
immunostained with rabbit polyclonal anti-GFAP
(DAKO; Carpinteria, CA) to label glia and mouse mono-
clonal anti-beta III tubulin antibody to (Promega; Madi-
son, WI) to identify neurons then eGFP was directly
visualized using a Spot Flex digital cameral (Diagnostic
Instruments, Sterling Heights, MI) attached to a Leica
DMLB microscope (Wetzlar, Germany). For qualitative
comparison of eGFP intensity, equivalent fields from
injection sites were captured using identical objectives
and microscope/camera settings.
Statistical Analysis
Statistical analysis was performed using general linear
models of SAS version 9.1 (Cary, NC) to determine the
gene expression differences in APP21, APP31 and WT rats,
as well as differences in serum Aβ concentrations.
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